| [1] |
Mao YS, Gao YN, He J, et al. Association of molecular biology of lung cancers and their metastasis and prognosis[J]. Zhonghua Zhong Liu Za Zhi, 2006, 28(8): 632-4.[毛友生, 高燕宁, 赫捷, 等. 肺癌分子生物学特性与转移和预后的关系[J]. 中华肿瘤杂志, 20 06, 8(8): 632-4.]
|
| [2] |
Yang HJ, Gu Y, Chen C, et al. Diagnostic value of pro-gastrinreleasing peptide for small cell lung cancer: a meta-analysis[J]. Clin Chem Lab Med, 2011, 49(6): 1039-46.
|
| [3] |
Scott A, Salgia R. Biomarkers in lung cancer: from early detection to novel therapeutics and decision making[J]. Biomark Med, 20 08, 2(6): 577-86.
|
| [4] |
Gao YC, Wang MQ, Lu Y, et al. The value of serum tumor markers in the diagnosis of lung cancer patients[J]. Zhonghua Jie He He Hu Xi Za Zhi, 2005, 28(4): 268-9.[高云朝, 王美琴, 陆云, 等. 血 清肿瘤标志物的检测对肺癌患者的诊断价值[J]. 中华结核和呼 吸杂志, 2005, 28(4): 268-9.]
|
| [5] |
Plebani M, Basso D, Navaglia F, et al. Clinical evaluation of seven tumor market in lung cancer diagnosis: can any combination improve the results[J]. Br J Cancer, 1995, 72(1): 170-3.
|
| [6] |
Sun J, Liu J, Yang BJ. The clinical value of serum pro-gastrinreleasing peptide and neuron-specific enolase for small-cell lung cancer[J]. Xian Dai Jian Yan Yi Xue Za Zhi, 2005, 20(4): 11-3.[孙 静, 刘静, 杨炳军. 胃泌素释放肽前体和神经元特异性烯醇化 酶对小细胞肺癌的临床应用价值[J]. 现代检验医学杂志, 2005, 20 (4): 11-3.]
|
| [7] |
Jin X, Chen JK, Tong YL, et al. Clinical significance of Pro-GRP in diagnosis of SCLC[J].Jun Shi Yi Xue Ke Xue Yuan Yuan Kan, 20 06, 30(4): 354-6.[金欣, 陈建魁, 佟雅丽, 等. 血清ProGRP对 小细胞肺癌的诊断和疗效判断价值[J]. 军事医学科学院院刊, 20 06, 30(4): 354-6.]
|
| [8] |
Duffy MJ, O’Donovan N, Crown J. Use of molecular markers for predicting therapy response in cancer patients[J]. Cancer Treat Rev, 2011, 37(2): 151-9.
|
| [9] |
Sturgeon CM, Hoffman BR, Chan DW, et al. National academy of clinical biochemistry laboratory medicine practice guidelines for use of tumor markers in clinical practice: quality requirements[J]. Clin Chem, 2008, 54(8): e1-10.
|
| [10] |
Wang Y, Huang LS, Huang WC. Clinical value of three kinds of serum tumor markers in the diagnosis of lung cancer[J]. Yi Xue Lin Chuang Yan Jiu, 2006, 23(5): 661-2, 665.[王英, 黄玲莎, 黄 文成. 三种血清肿瘤标志物在肺癌诊断中的临床价值[J]. 医学 临床研究, 2006, 23(5): 661-2, 665.]
|
| [11] |
Ma J, Zhao J, Jiang HJ. The application of pleural effusions tumor markers combined detection for lung cancer pathology classification and clinical staging[J]. Lin Chuang Yi Xue, 2008, 28 (7): 51-3.[马静, 赵俊, 蒋会娟．胸腔积液肿瘤标志物联合检 测在肺癌病理分型及临床分期中的应用[J]. 临床医学, 2008, 28 (7): 51-3.]
|
| [12] |
Deng X, Xiu X, Tan AG. Prognostic significance of CYFRA21-1 and CEA in stage Ⅲ non-small cell lung cancer[J]. Zhongguo Shi Yan Zhen Duan Xue, 2007, 11(6): 779-81.[邓湘, 修霞, 谭爱国. CYFRA21-1和CEA对Ⅲ期非小细胞肺癌患者的临床预后意义 [J] 中国实验诊断学, 2007, 11(6): 779-81.]
|
| [13] |
Merle P, Janicot H, Filaire M, et al. Early CYFRA21-1 variation predicts tool response to chemotherapy and survival in locally advanced non-small cell cancer patients[J]. Int J Biol Markers, 20 04, 19(4): 310-5.
|
| [14] |
Yang L, Tan LX, Jia ZC, et al. Lung cancers 69 cases sufferer,s serum tumor marker measurement analysis[J].Zhongguo Xian Dai Yi Xue Za Zhi, 2006, 8(2): 20-2.[杨玲, 谭立欣, 贾支朝, 等. 肺 癌患者69例血清肿瘤标志物测定分析[J]. 中国现代医学杂志, 20 06, 8(2): 20-2.]
|
| [15] |
Guo DW, Meng DY, Ding XN, et al. Serum CEA, CA125 levels analysis and its clinical significance for lung cancer patients[J]. Zhong Liu Fang Zhi Yan Jiu, 2002, 29(4): 275.[郭大文, 孟冬娅, 丁笑难, 等. 肺癌患者血清CEA、CA125水平分析及其临床意 义[J] 肿瘤防治研究, 2002, 29(4): 275.]
|
| [16] |
Molina R, Augé JM, Bosch X, et al. Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology[J]. Tumour Biol, 2009, 30 (3): 121-9.
|
| [17] |
Li MX, Wang D, Li ZP, et al. Establishment of diagnostic equation within serum multiple tumor markers and its significance in diagnosis and classify of lung cancer[J].Chongqing Yi Xue, 2007, 36 (19): 1926-8, 1972.[李梦侠, 王东, 李增鹏, 等. 血清多肿瘤标 志物判别方程建立及其对肺癌诊断及分类的意义[J]. 重庆医 学, 2007, 36(19): 1926-8, 1972.]
|
| [18] |
Nan YD, Tian YX, Yang SY, et al. Fisher discriminated analysis of Serum tumor markers on SCLC and NSCLC[J]. Xian Dai Zhong Liu Yi Xue, 2008, 16(3): 365-7.[南岩东, 田应选, 杨拴盈, 等. 血清肿瘤标志物对SCLC和NSCLC的Fisher判别分析[J]. 现 代肿瘤医学, 2008, 16(3): 365-7.]
|
下载:
